One-Year Neoadjuvant Endocrine Therapy in Breast Cancer

Pathology Oncology Research : POR
Orsolya RuszZsuzsanna Kahán

Abstract

The evaluation of the effects of 1-year endocrine therapy (NET) was aimed at. A retrospective analysis of 42 cases with 46 stage II-III invasive, hormone receptor-positive, HER2-negative breast cancers was performed. One-year NET was planned with letrozole (n = 33, postmenopausal group), or with goserelin plus letrozole (n = 7) or with goserelin plus tamoxifen (n = 2) (premenopausal group). Surgery was performed in accordance with the initial stage and the response to therapy. With regard to the tumor remaining in the surgical specimen, risk groups were constructed: Group 1: stage 0, pathological complete regression (pCR); Group 2: stages IA-IIA; Group 3: stages ≥ IIB + cases with clinical progression. Due to local progression, NET was replaced by neoadjuvant chemotherapy in three patients (four tumors). In two postmenopausal patients, letrozole was replaced by tamoxifen because of the insufficient treatment effect. In 19/42 cases, breast-conserving surgery was performed. Within Group 1, there was no cancer in four cases, while only DCIS remained in 2 (pCR: 13 %); Groups 2 and 3 comprised 25 and 15 cases, respectively. The likeliness of a good response (Groups 1 and 2 vs. Group 3) to NET was increased by 7 % for every 1 % incre...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitch DowsettRoger A'Hern
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Feb 12, 2008·Breast Cancer Research and Treatment·J Michael DixonWilliam R Miller
Aug 19, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DeCensiB Bonanni
Jun 7, 2011·The Lancet Oncology·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group
Dec 31, 2011·The Journal of Steroid Biochemistry and Molecular Biology·Jürgen GeislerWilliam Miller
Jun 1, 2012·The New England Journal of Medicine·Tatiana M Prowell, Richard Pazdur
Jun 2, 2012·The Lancet Oncology·Debora FumagalliUNKNOWN BIG-NABCG collaboration
Jul 31, 2013·Cancer Treatment Reviews·A CharehbiliC J H van de Velde
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Feb 25, 2014·Breast Cancer Research and Treatment·Robert CarpenterAnthony I Skene
Jun 3, 2014·The New England Journal of Medicine·Olivia PaganiUNKNOWN International Breast Cancer Study Group

❮ Previous
Next ❯

Citations

Jan 19, 2016·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·P A van DamX B Trinh
Aug 23, 2020·Current Opinion in Oncology·Dario Trapani, Giuseppe Curigliano
Apr 10, 2021·Breast Cancer : Targets and Therapy·Tara HyderAdam M Brufsky
Jun 3, 2021·Cancers·Covadonga Martí, José Ignacio Sánchez-Méndez
Mar 12, 2021·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Miki IwamotoRyuji Ohashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.